CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
GAITHERSBURG, Md., Jan. 05, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced that management will present at the 35th Annual J.P. Morgan Healthcare Conference.
Presentation details are as follows:
Date: Thursday, January 12, 2017
Time: 9:30 am U.S. Pacific Time
Location: California East room, Westin St. Francis Hotel, San Francisco
Live webcast: novavax.com, “Investors”/ “Events”
The webcast and replay of the presentation will also be accessible under the “Investors/Events” section of the website at novavax.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
